Crossmark

Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Crossref DOI link: https://doi.org/10.1016/j.endoen.2016.09.006

Published Print: 2016-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Puig-Domingo, Manuel

Soto, Alfonso

Venegas, Eva

Vilchez, Ricardo

Blanco, Concepción

Cordido, Fernando

Lucas, Tomás

Marazuela, Mónica

Casany, Rosa

Cuatrecasas, Guillem

Fajardo, Carmen

Gálvez, María Ángeles

Maraver, Silvia

Martín, Tomás

Romero, Enrique

Paja, Miguel

Picó, Antonio

Bernabeu, Ignacio

Resmini, Eugenia
License Information

Text and Data Mining valid from 2016-10-01
More Information

This article is maintained by: Elsevier

Article Title: Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Journal Title: Endocrinología y Nutrición (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.endoen.2016.09.006

Content Type: article

Copyright: © 2016 SEEN. Published by Elsevier España, S.L.U. All rights reserved.